Multiple Myeloma Therapeutics in Major Developed Markets is on Growth and forecast 2021.

2016-02-08 1

Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000.
For full report visit@http://tinyurl.com/zqdj3t9